Physician profile
Muhammad Y Ebrahim
NPI 1689654071
$13,101.74
in general payments reported to CMS, 2019-2025
35 companies · $1,740 in 2025
The $1,740 reported for 2025 was more than what 88% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $1,082 · 2021: $1,194 · 2022: $1,843 · 2023: $2,134 · 2024: $3,736 · 2025: $1,740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,619 · Travel and Lodging: $1,618 · Education: $373.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,618.78 |
| Travel and Lodging | $1,618.30 |
| Education | $373.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $1,668.30 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $1,359.39 | 2019-2025 | Jynarque, Voyxact |
| Astrazeneca Pharmaceuticals LP | $1,075.62 | 2019-2025 | Farxiga, Lokelma, Andexxa |
| Amgen INC. | $845.19 | 2019-2025 | Tavneos, Krystexxa, Parsabiv |
| Bayer Healthcare Pharmaceuticals INC. | $837.97 | 2021-2025 | |
| Travere Therapeutics, INC. | $603.88 | 2022-2025 | Filspari |
| Mallinckrodt Hospital Products INC. | $596.34 | 2020-2025 | Acthar, Terlivaz |
| Vifor Pharma, INC. | $588.95 | 2019-2025 | Veltassa |
| Akebia Therapeutics INC | $572.46 | 2019-2025 | Vafseo, Auryxia |
| Glaxosmithkline, LLC. | $485.63 | 2019-2025 | Benlysta, Jesduvroq, Shingrix |
| Aurinia Pharma U.S., INC. | $477.10 | 2021-2025 | Lupkynis |
| Horizon Therapeutics Plc | $471.51 | 2019-2023 | Krystexxa |
| Calliditas Therapeutics US INC. | $421.34 | 2022-2025 | Tarpeyo |
| Novartis Pharmaceuticals Corporation | $390.60 | 2019-2025 | |
| Opko Pharmaceuticals, LLC | $365.43 | 2019-2025 | Rayaldee |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $358.63 | 2022-2025 | Purified Cortrophin Gel |
| Novo Nordisk INC | $314.69 | 2023-2025 | Ozempic, Rivfloza, Rybelsus |
| Alexion Pharmaceuticals, INC. | $286.60 | 2019-2025 | Ultomiris |
| Mallinckrodt Enterprises LLC | $267.93 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $153.66 | 2023-2024 | Jardiance |
| Lilly USA, LLC | $138.83 | 2024-2025 | Jardiance |
| Nuwellis, INC. | $137.72 | 2020-2024 | Aquadex Smartflow Console |
| Daiichi Sankyo INC. | $115.29 | 2020-2022 | |
| Arbor Pharmaceuticals, INC. | $98.26 | 2019-2020 | |
| Recor Medical INC | $76.20 | 2024-2025 | Paradise Ultrasound Renal Denervation System, Paradise Renal Denervation System |
| Scpharmaceuticals INC. | $74.11 | 2025 | |
| Baxter Healthcare | $72.71 | 2019 | |
| Fresenius USA Marketing, INC. | $64.47 | 2020-2023 | Velphoro |
| Ultragenyx Pharmaceutical INC. | $61.17 | 2019-2020 | |
| Ardelyx, INC. | $41.52 | 2024 | Ibsrela |
| Cormedix INC. | $18.67 | 2025 | Defencath |
| Kyowa Kirin, INC. | $17.44 | 2023 | Crysvita |
| Tactile Systems Technology INC | $15.85 | 2024 | Flexitouch Plus, Entre Plus |
| Eisai INC. | $15.08 | 2019 | |
| Rockwell Medical, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Ebrahim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.